David Tuveson, MD, PhD, is professor and deputy director of the Cancer Center at Cold Spring Harbor Laboratory. Dr. Tuveson trained at MIT (BS, Chemistry, 1987), Johns Hopkins (MD, PhD 1994), Brigham and Women's Hospital (House Officer 1994-7) and Dana-Farber/Harvard (Medical Oncology Fellow 1997-2000). While at Dana-Farber, he co-developed Imatinib with George Demetri for patients with gastrointestinal stromal tumors (GIST). He was appointed an Assistant Professor of Medicine at the University of Pennsylvania from 2002–2006, where his laboratory developed the first ductal pancreatic cancer models. 

Dr. Tuveson was recruited in 2006 to the CRUK/Cambridge Research Institute at the University of Cambridge to establish a preclinical therapeutics laboratory and a pancreatic cancer clinical trials group. He was then recruited to Cold Spring Harbor Laboratory in 2012 to lead the Cancer Therapeutics Initiative. In 2015, Dr. Tuveson co-developed pancreatic cancer organoid models with Dr. Hans Clevers, a new platform for basic discovery and translational medicine. Dr. Tuveson also serves as Director of Research for the Lustgarten Foundation for Pancreatic Cancer Research, and has an appointment in medical oncology at Memorial Sloan Kettering Cancer Center. Past prizes include the Rita Allen Foundation award and the Jan Waldenstrom Award.